ALLEYN THOMAS PLOWRIGHT,LARS JOHAN ANDREAS ULANDER,DANIEL TOR PETTERSEN,MALIN ANITA LEMURELL,KENNETH LARS GRANBERG,HANS FREDRIK EMTENS,JOHAN OLOF BRODDEFALK
申请号：
ARP160101257
公开号：
AR104512A1
申请日:
2016.05.03
申请国别(地区):
AR
年份:
2017
代理人:
摘要：
For the treatment and / or prevention of clinical diseases including cardiovascular diseases (CVD),A method for treatment, pharmaceutical ingredients containing these substances and process for the preparation of these compounds. Claim 1: a compound calculated according to formula (1),or a pharmaceutically acceptable salt thereof, where: R¹ is H, C₁₋₃ alkyl,halo, C₁₋₃ alkoxy,a. Haloalkyl c83218c83331-83323；2. Each R2 and R3 is an independent h, lease land c833218331；C₁₋₃ alkoxy,-CN o halo R es H -CH-CH₂F, -CHF₂,-CF8323,Or halo, ring a contains two double links, each x1,X2,X3 and x83080 independent cr83099 of a ring a；CH, O, s, nr8310o n； at least one x1,X2,X3 and x830808 of a ring a are nr8310a；each R⁵ is optionally and independently C alquilo alkyl,C₁₋₆ alkoxy,Halogenated tar c83218323；C₁₋₃ haloalkoxy,-S (O) R-CN -CONRR o cicloalquilo CEach P is an independent 0, 1 or 2； r8310es h-ch-8323o-ch8322； ch832323；Or cr.83099 for x830808 and n.8310a for X3；Therefore, r83099 and r8310a can form an acyclic ring a with 5 to 6 members. The acyclic heteroplasm may include an extra heteroatom selected from n, O and s. The mixed heteroplasm may also contain a carbon or s (o) 832222, which is directly adjacent to the heteroatom； a. This alternative； one or two alternatives selected from the ch832323 and halo groups； r8311es-ch8323o-nrr； and each R and R is an independent h-o-ch83223；a. The total number of substitutes in ring a is 0, 1 or 2； in addition, if r83099 and r8310a are not mixed into a non ring fused with ring a, the total number of substitutes in r83099 and r8310a as lessor and / or halogenated tar is 0 or 1；A su uso en el tratamiento y/o prevención de afecciones clínicas que incluyen enfermedades cardiovasculares (CVD), a métodos para su uso terapéutico, a composiciones farmacéuticas que los contienen y a procesos para preparar dichos compuestos. Reivindicación 1: Un compuesto de acuerdo con la fórmula (1), o una sal farmacéuticamente aceptable de este, donde: R¹ es H,
